Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Progression02:07

Tumor Progression

7.9K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.9K
Tumor Progression02:07

Tumor Progression

3.6K
3.6K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
1.5K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

6.6K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
6.6K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

6.0K
6.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

NCCN Guidelines® Insights: Soft Tissue Sarcoma, Version 1.2025.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

Comparing Whole-Body Diffusion-weighted MRI to Conventional Imaging: Staging Pediatric Bone and Soft-Tissue Sarcomas.

Radiology. Imaging cancer·2025
Same author

ESFT13: A Phase II Study Evaluating the Addition of Window and Maintenance Therapy to a Standard Chemotherapy Backbone for the Treatment of High-Risk Ewing Sarcoma.

Cancers·2025
Same author

Acute cardiotoxicity in pediatric and adolescent patients with solid tumors treated with tyrosine kinase inhibitors.

Cancer·2025
Same author

The Evolving Landscape of Sarcomas.

Hematology/oncology clinics of North America·2025
Same author

Clinicopathologic Features, Management, and Outcomes Of Pediatric CRTC1::TRIM11 and MED15::ATF1 Tumors With Spitzoid Morphology: A Case Series.

Pediatric blood & cancer·2025

Related Experiment Video

Updated: Apr 5, 2026

Establishment of Orthotopic Patient-derived Xenograft Models for Brain Tumors using a Stereotaxic Device
07:44

Establishment of Orthotopic Patient-derived Xenograft Models for Brain Tumors using a Stereotaxic Device

Published on: May 2, 2025

1.1K

Rare Tumors in Children: Progress Through Collaboration.

Alberto S Pappo1, Wayne L Furman2, Kris A Schultz2

  • 1Alberto S. Pappo and Wayne L. Furman, St Jude Children's Research Hospital, Memphis, TN; Kris A. Schultz, Children's Hospital of Minnesota, Minneapolis, MN; Andrea Ferrari, Instituto Nazionale Tumori, Milano, Italy; Lee Helman, National Cancer Institute Center for Cancer Research, Bethesda, MD; and Mark D. Krailo, Keck School of Medicine, Los Angeles, CA. alberto.pappo@stjude.org.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|August 26, 2015
PubMed
Summary

Investigating rare pediatric tumors is challenging due to their diversity. Current collaborative efforts show limited success, prompting exploration of new strategies like independent registries for studying childhood cancers.

More Related Videos

A Brain Tumor/Organotypic Slice Co-culture System for Studying Tumor Microenvironment and Targeted Drug Therapies
10:13

A Brain Tumor/Organotypic Slice Co-culture System for Studying Tumor Microenvironment and Targeted Drug Therapies

Published on: November 7, 2015

11.8K
A Protocol for Rapid Post-mortem Cell Culture of Diffuse Intrinsic Pontine Glioma DIPG
08:46

A Protocol for Rapid Post-mortem Cell Culture of Diffuse Intrinsic Pontine Glioma DIPG

Published on: March 7, 2017

17.6K

Related Experiment Videos

Last Updated: Apr 5, 2026

Establishment of Orthotopic Patient-derived Xenograft Models for Brain Tumors using a Stereotaxic Device
07:44

Establishment of Orthotopic Patient-derived Xenograft Models for Brain Tumors using a Stereotaxic Device

Published on: May 2, 2025

1.1K
A Brain Tumor/Organotypic Slice Co-culture System for Studying Tumor Microenvironment and Targeted Drug Therapies
10:13

A Brain Tumor/Organotypic Slice Co-culture System for Studying Tumor Microenvironment and Targeted Drug Therapies

Published on: November 7, 2015

11.8K
A Protocol for Rapid Post-mortem Cell Culture of Diffuse Intrinsic Pontine Glioma DIPG
08:46

A Protocol for Rapid Post-mortem Cell Culture of Diffuse Intrinsic Pontine Glioma DIPG

Published on: March 7, 2017

17.6K

Area of Science:

  • Pediatric Oncology
  • Rare Cancer Research
  • Clinical Trial Design

Background:

  • Rare pediatric tumors represent a significant challenge in childhood cancer research, accounting for approximately 10% of all pediatric malignancies.
  • The histological and clinical heterogeneity of these rare tumors complicates the study of their biological and clinical characteristics.
  • Existing national and international cooperative initiatives have faced limitations in advancing knowledge about rare pediatric cancers.

Purpose of the Study:

  • To review current national and international collaborative strategies for studying rare pediatric cancers.
  • To explore alternative mechanisms for enhancing research efforts in rare pediatric oncology.
  • To identify novel approaches for investigating the biology and clinical features of rare childhood tumors.

Main Methods:

  • Review of existing literature and initiatives from cooperative groups like the Children's Oncology Group and European Cooperative Study Group for Pediatric Rare Tumors.
  • Analysis of the effectiveness of current collaborative programs in rare pediatric cancer research.
  • Exploration of alternative study mechanisms, including independent registries and disease-specific clinics.

Main Results:

  • Current collaborative programs have demonstrated partial effectiveness in advancing the study of rare pediatric tumors.
  • There is a recognized need for alternative and enhanced strategies to overcome the limitations of existing collaborative efforts.
  • Independent registries and National Cancer Institute-sponsored clinics are being explored as promising alternative mechanisms.

Conclusions:

  • Enhanced collaborative strategies are crucial for advancing the understanding and treatment of rare pediatric cancers.
  • Alternative approaches such as independent registries and specialized clinics show potential for improving research outcomes.
  • Continued innovation in study design and collaboration is necessary to address the challenges posed by rare childhood tumors.